Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055523 · ClinicalTrials.gov registry record · Phase 2
A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
A Phase 2 study of Crohn's Disease, sponsored by Abbott.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT00055523: Completed Phase 2 study of Crohn's Disease, sponsored by Abbott.
NCT00055523 is a Phase 2 study of Crohn's Disease that has completed, run by Abbott. The registered enrollment target is 300 participants, below the 2,392-participant average among 105 other Crohn's Disease trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00055523, a Phase 2 study of Crohn's Disease, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
Purpose of the study is to test whether adalimumab can induce clinical remission in subjects with active Crohn's disease when compared to placebo (an inactive substance)
Conditions Studied
Interventions
- DRUG Adalimumab (D2E7)
Study Locations (20)
California
- Gastroenterology Associates of the East Bay - Berkeley
- Long Beach Gastroenterology Assoc. - Long Beach
- Sharp Rees-Stealy Medical Group - San Diego
Massachusetts
- Brigham and Women's Hospital - Boston
- Massachusetts General Hospital - Boston
- Clinical Pharmacology Study Group - Worcester
Florida
- Cleveland Clinic Florida - Weston
- Shafran Gastroenterology Center - Winter Park
Georgia
- Atlanta Gastroenterology Assoc. - Atlanta
- Southeastern Digestive & Liver Disease - Savannah
Illinois
- Northwest Gastroenterologists, S.C. - Arlington Heights
- University of Chicago - Chicago
Louisiana
- Drug Research Services, Inc. - Metairie
- LSU School of Medicine - New Orleans
Missouri
- Gastroenterology and Hepatology - Kansas City
- Glenn Gordon, MD - Mexico
Connecticut
- Gastroenterology Assoc. of Fairfield Co. - Bridgeport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2002-04 |
| Phase | Phase 2 |
What the finished NCT00055523 record still lists
NCT00055523 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 2,392-participant average among 105 other Crohn's Disease trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which Adalimumab (D2E7) is the first listed.
NCT00055523 names 20 study sites across 11 states, led by California, Massachusetts, Florida.
Frequently Asked Questions
What is clinical trial NCT00055523 about?
NCT00055523 is a clinical study titled "A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease". Purpose of the study is to test whether adalimumab can induce clinical remission in subjects with active Crohn's disease when compared to placebo (an inactive substance)
What is the current status of trial NCT00055523?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2002-04.
What conditions does trial NCT00055523 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT00055523?
The interventions under investigation include: Adalimumab (D2E7) (DRUG).
Who is sponsoring clinical trial NCT00055523?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00055523 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00055523's enrollment target sits among peer trials
300 37th of 105 higher than 66 of 105 other Crohn's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
RECRUITING · Phase 2
-
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia